Jeff Yass’s Xenon Pharmaceuticals XENE Stock Holding History

Jeff Yass’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.38M	Sell	72,500 -978,400	-93%	-$54.3M	﹤0.01%	4888
2026 Q1	$61.1M	Buy	1,050,900 +1,001,900	+2,045%	+$46.2M	0.01%	1140
2025 Q4	$2.2M	Sell	49,000 -38,900	-44%	-$1.63M	﹤0.01%	5456
2025 Q3	$3.53M	Buy	87,900 +2,600	+3%	+$91.6K	﹤0.01%	4674
2025 Q2	$2.67M	Buy	+85,300	New	+$2.78M	﹤0.01%	5197
2024 Q3	–	Sell	-28,300	Closed	-$1.1M	–	13178
2024 Q2	$1.1M	Sell	28,300 -4,900	-15%	-$196K	﹤0.01%	6351
2024 Q1	$1.43M	Sell	33,200 -2,500	-7%	-$115K	﹤0.01%	6115
2023 Q4	$1.64M	Buy	35,700 +3,100	+10%	+$110K	﹤0.01%	5777
2023 Q3	$1.11M	Sell	32,600 -3,200	-9%	-$120K	﹤0.01%	6393
2023 Q2	$1.38M	Buy	+35,800	New	+$1.42M	﹤0.01%	5952
2023 Q1	–	Sell	-10,700	Closed	-$422K	–	13602
2022 Q4	$422K	Sell	10,700 -15,000	-58%	-$546K	﹤0.01%	8293
2022 Q3	$928K	Sell	25,700 -23,000	-47%	-$827K	﹤0.01%	6819
2022 Q2	$1.48M	Sell	48,700 -16,800	-26%	-$508K	﹤0.01%	5563
2022 Q1	$2M	Sell	65,500 -14,100	-18%	-$422K	﹤0.01%	5474
2021 Q4	$2.49M	Sell	79,600 -91,800	-54%	-$2.74M	﹤0.01%	5011
2021 Q3	$2.62M	Buy	+171,400	New	+$2.98M	﹤0.01%	5250

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Jeff Yass's XENE Position: Q2 2026 in Review

Jeff Yass reduced its Xenon Pharmaceuticals (XENE) stake by 87% in Q2 2026, selling an estimated $8.6M and leaving 22,258 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #7440.

Jeff Yass first reported a position in XENE in Q2 2017 and has held it in 16 quarters since. The position peaked at $10.3M in Q1 2026. 314 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Jeff Yass held 22,258 shares of Xenon Pharmaceuticals worth $1.34M as of Q2 2026.
Jeff Yass sold 154,879 Xenon Pharmaceuticals shares in Q2 2026, an estimated $8.6M.
Xenon Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7440 holding.
Jeff Yass first reported a position in Xenon Pharmaceuticals in Q2 2017 and has held it in 16 quarters since.
Jeff Yass's Xenon Pharmaceuticals position peaked at $10.3M in Q1 2026.
314 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.